A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis
Status:
Completed
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
The aim of the trial is to assess the safety and efficacy of the orally-administered,
selective complement C5a receptor inhibitor CCX168 (avacopan) in inducing and sustaining
remission in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis
(AAV).